ID   TCC-NECT-2
AC   CVCL_WS42
DR   cancercelllines; CVCL_WS42
DR   JCRB; JCRB1916
DR   Wikidata; Q98133180
RX   PubMed=29765522;
RX   PubMed=30559933;
CC   Population: Japanese.
CC   Doubling time: ~31.4 hours (PubMed=30559933).
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=30559933).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; c.783-1G>A; ClinVar=VCV000458565; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=30559933).
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
ST   Source(s): JCRB=JCRB1916
ST   Amelogenin: X
ST   CSF1PO: 13
ST   D13S317: 9,11
ST   D16S539: 10,13
ST   D5S818: 11
ST   D7S820: 10
ST   TH01: 9
ST   TPOX: 8
ST   vWA: 18,20
DI   NCIt; C135080; Duodenal neuroendocrine tumor
DI   ORDO; Orphanet_100076; Duodenal neuroendocrine tumor
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   59Y
CA   Cancer cell line
DT   Created: 05-07-19; Last updated: 19-12-24; Version: 11
//
RX   PubMed=29765522; DOI=10.18632/oncotarget.24930; PMCID=PMC5940407;
RA   Ohmoto A., Suzuki M., Takai E., Rokutan H., Fujiwara Y., Morizane C.,
RA   Yanagihara K., Shibata T., Yachida S.;
RT   "Establishment of preclinical chemotherapy models for
RT   gastroenteropancreatic neuroendocrine carcinoma.";
RL   Oncotarget 9:21086-21099(2018).
//
RX   PubMed=30559933; DOI=10.18632/oncotarget.26367; PMCID=PMC6284856;
RA   Yanagihara K., Kubo T., Mihara K., Kuwata T., Ochiai A., Seyama T.,
RA   Yokozaki H.;
RT   "Establishment of a novel cell line from a rare human duodenal poorly
RT   differentiated neuroendocrine carcinoma.";
RL   Oncotarget 9:36503-36514(2018).
//